Form 4: Entrada Therapeutics' President & COO, Nathan J Dowden, Reports Changes in Beneficial Ownership

Nathan J Dowden, President & COO of Entrada Therapeutics, reports acquisition of restricted stock units and stock options, as well as a sale of shares to cover tax obligations.

Summary

• On March 1, 2025, Nathan J Dowden, President & COO of Entrada Therapeutics, was granted 60,800 restricted stock units (RSUs) and 90,800 stock options.
• The RSUs vest in four equal installments on March 1st of 2026, 2027, 2028 and 2029.
• The stock options vest 25% on March 1, 2026, and the remaining 75% vest in 36 equal monthly installments thereafter, fully vesting on March 1, 2029.
• On March 3, 2025, Dowden sold 5,144 shares of common stock at a weighted average price of $11.6786 to cover tax withholding obligations related to the vesting of previously granted RSUs.
• Following these transactions, Dowden directly owns 180,805 shares of common stock and 90,800 stock options.
• The reported transactions were filed with the SEC on March 4, 2025.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment, as it primarily reports transactions related to executive compensation. The information is factual and does not inherently indicate positive or negative performance for the company.

Positives

• Grant of RSUs and stock options to the President & COO aligns his interests with those of the shareholders.
• The vesting schedules for the RSUs and stock options encourage long-term commitment from the executive.

Negatives

• Sale of shares to cover tax obligations, although common, could be perceived negatively if the amount is significant.

Risks

• Executive's decisions could be influenced by the vesting schedule of the RSUs and stock options.
• Future sales of shares by the executive could put downward pressure on the stock price.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. This filing indicates changes in the holdings of a key executive at Entrada Therapeutics.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in the biotechnology industry.
• Vesting schedules of 3-4 years are typical for such grants, aligning with industry standards for incentivizing long-term performance.
• Companies like Moderna and BioNTech also utilize stock options and RSUs as part of their executive compensation packages, with similar vesting schedules.

Stakeholder Impact

• Shareholders may view the grant of RSUs and stock options as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see the executive's increased stake in the company as a motivator for strong leadership.

Key Dates